ArticleRevista panamericana de salud publica = Pan American journal of public health2025
[Emergency authorization of vaccines in countries of the Americas, August 2024Autorização de vacinas em situações de emergência nos países da Região das Américas, agosto de 2024].
Article in Revista panamericana de salud publica = Pan American journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the post-pandemic regulatory preparedness of countries of the Region of the Americas for emergency authorization of vaccines as of August 2024 and propose recommendations for future public health emergencies. Methods: Special report describing the mechanisms for emergency use authorization of vaccines established in the regulatory frameworks of Latin American and English-speaking Caribbean countries. Results: Most of the countries (64%) included in this analysis did not make any changes in their regulations for emergency situations following the COVID-19 pandemic. Special import permits constitute the most common established mechanism for emergency authorization (82%). Regulatory reliance-based mechanisms were found in a minority of countries (32%), as were emergency use authorization, provisional marketing authorization, or fast-track registration mechanisms (23%). Only reliance-based mechanisms were found to use risk criteria based on the source from which vaccines were obtained. Conclusions: This analysis reflects the need to strengthen the Region's regulatory systems to address future public health emergencies and facilitate access to necessary vaccines. Furthermore, regulatory systems should adopt a regulatory approach based on risk criteria, with distinct procedures and requirements, as well as strengthen cooperation with other National Regulatory Authorities (NRAs) at the regional and global levels, to achieve greater regulatory efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.